Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 16, 2012

Primary Completion Date

March 29, 2018

Study Completion Date

March 29, 2018

Conditions
Adult B Acute Lymphoblastic LeukemiaAdult T Acute Lymphoblastic LeukemiaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaChronic Lymphocytic LeukemiaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueHepatosplenic T-Cell LymphomaIntraocular LymphomaLymphomatous Involvement of Non-Cutaneous Extranodal SiteMature T-Cell and NK-Cell Non-Hodgkin LymphomaNodal Marginal Zone LymphomaPrimary Cutaneous B-Cell Non-Hodgkin LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-Cell Leukemia/LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides and Sezary SyndromeRecurrent Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaSmall Intestinal LymphomaSplenic Marginal Zone LymphomaT-Cell Large Granular Lymphocyte LeukemiaTesticular LymphomaWaldenstrom Macroglobulinemia
Interventions
DRUG

Alisertib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Vorinostat

Given PO

Trial Locations (5)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

95817

University of California Davis Comprehensive Cancer Center, Sacramento

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01567709 - Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | Biotech Hunter | Biotech Hunter